1. Trimeric HIV-1 gp140 fused with APRIL, BAFF, and CD40L on the mucosal gp140-specific antibody responses in mice
- Author
-
Feng Yun Yue, Kiera L. Clayton, Chris Zealey, Wenbo Gao, Yuan Bie, Jordan A. Schwartz, Jun Liu, Mario A. Ostrowski, Yu Li, James M. Rini, and Patrick Budylowski
- Subjects
Recombinant Fusion Proteins ,CD40 Ligand ,Tumor Necrosis Factor Ligand Superfamily Member 13 ,030231 tropical medicine ,HIV Infections ,HIV Antibodies ,Epitope ,Mice ,03 medical and health sciences ,0302 clinical medicine ,B-Cell Activating Factor ,Animals ,030212 general & internal medicine ,B-cell activating factor ,Neutralizing antibody ,Immunity, Mucosal ,AIDS Vaccines ,CD40 ,General Veterinary ,General Immunology and Microbiology ,biology ,Chemistry ,env Gene Products, Human Immunodeficiency Virus ,Public Health, Environmental and Occupational Health ,Antibodies, Neutralizing ,Fusion protein ,In vitro ,Immunoglobulin A ,3. Good health ,Infectious Diseases ,Immunoglobulin G ,Antibody Formation ,Immunology ,HIV-1 ,biology.protein ,Molecular Medicine ,Female ,Tumor necrosis factor alpha ,Antibody - Abstract
HIV-1 envelope (Env)-specific antibody present at mucosal surfaces can block entry of HIV-1 into these portals and thus should be elicited by an HIV-1 preventive vaccine. Since three molecules of tumor necrosis factor superfamily (TNFSF), APRIL, BAFF, and CD40L, could promote mucosal antibody responses, we made fusion constructs of them with an HIV-1 gp140 trimer and tested the mucosal gp140-specific antibody elicited by the fusion constructs in mice using a DNA prime-protein boost vaccination regimen. The fusion constructs formed trimers and displayed both broadly neutralizing antibody epitopes and non-broadly neutralizing antibody epitopes. Compared with the control construct, trimeric gp140, trimeric gp140-APRIL and gp140-BAFF fusion proteins mildly promoted B cell proliferation in vitro, enhanced HIV-1 gp140-binding IgG responses in vaginal lavage or fecal pellets, respectively, and decreased HIV-1 gp140-binding IgA in sera. Gp140-APRIL also augmented HIV-1 gp140-binding IgG in sera. Surprisingly, gp140-CD40L did not promote B cell proliferation in vitro and inhibited mucosal and systemic HIV-1 gp140-binding IgG or IgA. These results suggest that APRIL and BAFF should be further explored as molecular adjuvants for HIV-1 vaccines to enhance mucosal antibody responses, but covalent fusion of TNFSFs to gp140 may hinder their adjuvancy due to steric interactions.
- Published
- 2020
- Full Text
- View/download PDF